Dapsone 100 Mg Tablet – Sulfone Antimicrobial & Anti-Inflammatory Therapy

Dapsone 100 Mg Tablet (diaminodiphenyl sulfone, DDS) is an oral synthetic sulfone medication with dual antimicrobial and potent immunomodulatory anti-inflammatory properties. It is clinically indicated for the management of dermatitis herpetiformis (Duhring’s disease), multidrug regimens for all forms of leprosy (Hansen’s disease), and treatment-resistant neutrophilic dermatoses, including severe inflammatory and nodulocystic acne vulgaris.

What Is Dapsone 100 Mg?

Dapsone (4,4′-diaminodiphenyl sulfone) is a synthetic sulfone compound with a long clinical history in both infectious diseases and clinical dermatology. It provides antibacterial and antiparasitic activity while suppressing chronic neutrophilic inflammatory pathways.

The 100 Mg strength is the standard therapeutic dose for adults. In dermatological practice, dapsone provides rapid control over intense burning, itching, and blistering in autoimmune skin conditions such as dermatitis herpetiformis, often producing dramatic relief within 48 to 72 hours.

Because dapsone is metabolized by hepatic N-acetylation and cytochrome P450-dependent N-hydroxylation into metabolites that cause oxidative stress on erythrocytes, patient screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency and routine baseline hematologic testing are mandatory before starting treatment.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

How Does Dapsone 100 Mg Work?

Dapsone acts via two distinct pharmacological mechanisms depending on the pathology being treated:

• Antimicrobial Folate Synthesis Inhibition: Similar to sulfonamides, dapsone competitively inhibits the enzyme dihydropteroate synthase (DHPS) in susceptible microorganisms. This halts the conversion of para-aminobenzoic acid (PABA) to dihydrofolate, stopping bacterial synthesis of folic acid and nucleic acids necessary for replication in Mycobacterium leprae and Pneumocystis jirovecii.
• Neutrophil & Immunomodulatory Suppression: In non-infectious inflammatory dermatoses, dapsone inhibits neutrophil myeloperoxidase (MPO) activity, blocks respiratory burst, downregulates tissue-destructive lysosomal enzyme release, and prevents neutrophil chemotaxis and integrin-mediated adhesion to vascular endothelial cells.

This selective suppression of neutrophil-mediated tissue damage resolves inflammatory papules, sterile microabscesses, and itchy subepidermal blisters without broadly suppressing systemic lymphocyte defenses.

What Is Dapsone 100 Mg Used For?

Dapsone 100 Mg is indicated for the treatment of multiple dermatological and infectious conditions:

• Dermatitis Herpetiformis (Duhring’s Disease): Primary therapeutic intervention to relieve severe pruritus and clear cutaneous vesicles in conjunction with a gluten-free diet.
• Leprosy (Hansen’s Disease): Essential multidrug therapy (MDT) component alongside rifampicin and clofazimine to eradicate Mycobacterium leprae and prevent secondary bacterial resistance.
• Refractory Severe Inflammatory Acne: Off-label oral therapy for deep, scarring, or nodulocystic acne in patients intolerant to or unresponsive to oral isotretinoin or standard tetracyclines.
• Neutrophilic & Autoimmune Dermatoses: Prescribed for Sweet’s syndrome, pyoderma gangrenosum, linear IgA bullous dermatosis, and cutaneous lupus erythematosus.
• Pneumocystis jirovecii Pneumonia (PCP) Prophylaxis: Alternative prophylactic regimen in immunocompromised individuals intolerant to trimethoprim-sulfamethoxazole.

Dapsone must be dosed under strict medical monitoring with regular laboratory assessments of complete blood counts and liver enzymes.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Related Dermatological Acne Therapy

For non-systemic, localized comedolytic care and follicular cell turnover management, explore our clinical overview of topical third-generation retinoid treatment:

Adaferin Gel 0.1% (15 gm)

Dapsone 100 Mg Dosage and Administration

Dapsone dosage is individualized based on diagnosis, clinical response, and hematologic tolerance:

• Dermatitis Herpetiformis: Standard starting dose is 50 Mg daily in adults. If full relief of burning and blistering is not achieved, the dose may be titrated upward to 100 Mg daily, and occasionally up to 300 Mg daily in severe disease. Once symptoms subside, reduce the dose to the lowest effective maintenance level (typically 50 Mg daily or on alternate days).
• Leprosy (Multidrug Therapy): 100 Mg orally once daily administered concurrently with other antileprotic agents (rifampicin and clofazimine) for 6 to 12 months as guided by WHO protocols.
• PCP Prophylaxis: 100 Mg orally once daily (or 50 Mg twice daily) as an alternative regimen under infectious disease supervision.

Tablets should be swallowed whole with a glass of water. Taking dapsone with meals or a glass of milk helps reduce minor gastrointestinal upset.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Dapsone 100 Mg vs Adaferin Gel 0.1% (Adapalene)

Comparing systemic sulfone therapy with topical retinoid therapy clarifies their distinct clinical applications in dermatology:

Dapsone provides systemic immunomodulation for inflammatory, neutrophilic, and blistering dermatoses, whereas Adaferin Gel normalizes skin desquamation at the follicle surface.

Who Should Not Take Dapsone 100 Mg?

Dapsone is contraindicated or requires caution under the following clinical conditions:

• Known hypersensitivity to dapsone, sulfones, or any excipients in the tablet
• Severe, uncompensated anemia or baseline hemoglobin < 9 g/dL
• Severe G6PD deficiency: Due to the risk of life-threatening acute intravascular hemolysis
• Significant cardiopulmonary disease where mild methemoglobinemia or reduced oxygen-carrying capacity could trigger ischemia
• Severe hepatic impairment (dapsone is extensively metabolized by the liver)
• Pregnancy and lactation (dapsone crosses the placenta and passes into breast milk; can cause neonatal hemolytic anemia and hyperbilirubinemia)

Patients must be educated regarding the symptoms of acute hemolysis and methemoglobinemia (cyanosis, sudden fatigue, shortness of breath, dark urine).
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Possible Side Effects of Dapsone 100 Mg

Adverse reactions associated with dapsone are predominantly hematologic and dermatologic:

• Hemolysis & Anemia: Dose-related reduction in red blood cell survival, reticulocytosis, and hemoglobin drops of 1 to 2 g/dL (more pronounced in G6PD-deficient individuals).
• Methemoglobinemia: Hydroxylamine metabolites oxidize hemoglobin to methemoglobin, causing cyanosis (bluish lips/fingers), dyspnea, fatigue, and headache.
• Dapsone Hypersensitivity Syndrome (DHS): A rare, potentially fatal triad of fever, exfoliative dermatitis, lymphadenopathy, and hepatitis, typically occurring 2 to 6 weeks after starting treatment.
• Agranulocytosis: Severe leukopenia, usually emerging within the first 2 to 3 months of therapy.
• Peripheral Neuropathy: Motor neuropathy manifesting as distal muscle weakness without sensory loss (e.g., foot drop), typically reversible upon discontinuation.
• Gastrointestinal: Nausea, vomiting, anorexia, and abdominal discomfort.

Seek immediate emergency medical evaluation if unexplained fever, sore throat, severe jaundice, dark urine, or bluish skin discoloration develops.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Dapsone 100 Mg Drug Interactions

Dapsone is metabolized by hepatic CYP3A4, CYP2C9, and CYP2C19 pathways, making it vulnerable to enzymatic interactions:

Rifampin: Strongly induces hepatic CYP enzymes, increasing dapsone clearance by up to 7- to 10-fold and lowering systemic dapsone levels (dose adjustments are common in MDT protocols).

Trimethoprim: Inhibits dapsone clearance and metabolism, elevating serum concentrations of both dapsone and trimethoprim, which increases the incidence of methemoglobinemia.

Cimetidine: Inhibits the CYP-mediated N-hydroxylation of dapsone into toxic hydroxylamine metabolites, occasionally utilized clinically to lessen dapsone-induced methemoglobinemia.

Oxidative & Hemolytic Drugs: Co-administration with other oxidant drugs (such as primaquine, nitrofurantoin, or rasburicase) multiplies hemolytic risks.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Mandatory Laboratory Monitoring Protocols

Due to bone marrow suppression, hemolysis, and hepatic toxicity risks, structured clinical monitoring is mandatory:

• Baseline Screening: Quantitative G6PD assay, complete blood count (CBC) with differential, reticulocyte count, baseline methemoglobin level, and liver function tests (LFTs).
• First 3 Months: CBC with differential and reticulocyte counts should be performed weekly for the first 4 weeks, then every 2 weeks through month 3 to detect early agranulocytosis or severe hemolytic crises.
• Long-Term Maintenance: CBC and liver panels should be re-evaluated every 3 to 4 months once patient hematologic counts stabilize.

Therapy must be interrupted if a marked drop in leukocytes, platelets, or red cell counts occurs.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2557e1bb-8dfd-4a11-b4f7-bf8ef2882be1))

Understanding Methemoglobinemia Management

Dapsone hydroxylamine metabolites oxidize the ferrous iron ($Fe^{2+}$) in hemoglobin into ferric iron ($Fe^{3+}$), producing methemoglobin, which cannot bind oxygen.

Most patients maintain asymptomatic methemoglobin levels between 5% and 15%. If methemoglobin levels exceed 20%, or if cyanosis, fatigue, and tachycardia become symptomatic, dapsone must be discontinued. Severe symptomatic methemoglobinemia (> 30%) is treated with intravenous methylene blue (1 to 2 mg/kg) or ascorbic acid under emergency medical supervision.

Official Medical Reference

For authoritative clinical pharmacology data, boxed hematologic warnings, dosing schedules, and contraindications for dapsone tablets, consult the official FDA DailyMed monograph:

DailyMed – Dapsone Tablets Official Prescribing Information

Frequently Asked Questions About Dapsone 100 Mg

Medical Disclaimer

This product overview is provided strictly for educational and informational purposes. Dapsone 100 Mg is a prescription sulfone medication requiring baseline enzymatic testing (G6PD), dosage titration, and frequent hematologic monitoring by a licensed physician or dermatologist. Individual tolerance and dosing depend on baseline red blood cell parameters, renal and hepatic health, and concurrent drug regimens. This content does not substitute for clinical medical advice, professional diagnosis, or personalized therapeutic care.